drugset / Trial / NCT04211259
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
Phase 0
Recruiting
70 enrolled
Rutgers, The State University of New Jersey
National Cancer Institute (NCI) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the process of stem cell collection in patients with multiple myeloma.
Timeline
- Start
- 2022-04-18
- Primary completion
- 2026-08-31
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Loratadine | Small molecule | — | Oral |